MedTrace Logo

Proton Radiation Therapy (RT) for the Treatment of Pediatric Rhabdomyosarcoma

NCT00592592 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 115

Last updated 2025-06-18

Study results available
· View outcomes & findings →

Summary

The main purpose of this study is to see if using proton beam radiation therapy instead of photon beam radiation therapy can reduce side effects from radiation treatment for rhabdomyosarcoma. Photon beam radiation is the standard type of radiation for treating most rhabdomyosarcoma and many other types of cancer. Photon beam radiation enters the body and passes through healthy tissue, encounters the tumor, then leaves the body through healthy tissue. A beam of proton radiation enters the body and passes through healthy tissue, encounters tumor, but then stops. This means that less healthy tissue is affected by proton beam radiation than by photon beam radiation.

Conditions

  • Rhabdomyosarcoma

Interventions

RADIATION

Proton Beam Radiation

Once per day, 5 days a week for a total of 4 to 6 weeks.

Sponsors & Collaborators

  • M.D. Anderson Cancer Center

    collaborator OTHER

  • Brigham and Women's Hospital

    collaborator OTHER

  • Boston Children's Hospital

    collaborator OTHER

  • Dana-Farber Cancer Institute

    collaborator OTHER

  • National Institutes of Health (NIH)

    collaborator NIH

  • National Cancer Institute (NCI)

    collaborator NIH

  • Massachusetts General Hospital

    lead OTHER

Principal Investigators

  • Torunn Yock, MD · Massachusetts General Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Max Age
30 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-10-31
Primary Completion
2010-08-31
Completion
2010-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00592592 on ClinicalTrials.gov